Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

CITED1 as a marker of favourable outcome in anti-endocrine treated, estrogen-receptor positive, lymph-node negative breast cancer.

Dahlgren, Malin LU ; Lettiero, Barbara LU ; Dalal, Hina LU orcid ; Mårtensson, Kira ; Gaber, Alexander LU ; Nodin, Björn LU ; Gruvberger, Sofia LU ; Saal, Lao H LU orcid and Howlin, Jillian LU (2023) In BMC Research Notes 16(1).
Abstract
Objective: To investigate CITED1 as a potential biomarker of anti-endocrine response and breast cancer recurrence, given its previously determined role in mediating estrogen-dependant transcription. The study is a continuation of earlier work establishing the role of CITED1 in mammary gland development.

Results: CITED1 mRNA is associated with estrogen-receptor positivity and selectively expressed in the GOBO dataset of cell lines and tumours representing the luminal-molecular subtype. In patients treated with tamoxifen, higher CITED1 correlated with better outcome, suggesting a role in anti-estrogen response. The effect was particularly evident in the subset of estrogen-receptor positive, lymph-node negative (ER+/LN-) patients... (More)
Objective: To investigate CITED1 as a potential biomarker of anti-endocrine response and breast cancer recurrence, given its previously determined role in mediating estrogen-dependant transcription. The study is a continuation of earlier work establishing the role of CITED1 in mammary gland development.

Results: CITED1 mRNA is associated with estrogen-receptor positivity and selectively expressed in the GOBO dataset of cell lines and tumours representing the luminal-molecular subtype. In patients treated with tamoxifen, higher CITED1 correlated with better outcome, suggesting a role in anti-estrogen response. The effect was particularly evident in the subset of estrogen-receptor positive, lymph-node negative (ER+/LN-) patients although noticeable divergence of the groups was apparent only after five years. Tissue microarray (TMA) analysis further validated the association of CITED1 protein, by immunohistochemistry, with favourable outcome in ER+, tamoxifen-treated patients. Although we also found a favourable response to anti-endocrine treatment in a larger TCGA dataset, the tamoxifen-specific effect was not replicated. Finally, MCF7 cells overexpressing CITED1 showed selective amplification of AREG but not TGFα suggesting that maintenance of specific ERα-CITED1 mediated transcription is important for the long-term response to anti-endocrine therapy. These findings together confirm the proposed mechanism of action of CITED1 and support its potential use as a prognostic biomarker. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
breast cancer, ER alpha, CITED1, tamoxifen, aromatase inhibitor, Anti-endocrine
in
BMC Research Notes
volume
16
issue
1
article number
105
publisher
BioMed Central (BMC)
external identifiers
  • scopus:85161830195
  • pmid:37322548
ISSN
1756-0500
DOI
10.1186/s13104-023-06376-1
language
English
LU publication?
yes
id
b26d598a-8202-43bb-90ac-7309d7625eee
date added to LUP
2023-07-30 20:35:12
date last changed
2024-02-23 07:16:38
@article{b26d598a-8202-43bb-90ac-7309d7625eee,
  abstract     = {{Objective: To investigate CITED1 as a potential biomarker of anti-endocrine response and breast cancer recurrence, given its previously determined role in mediating estrogen-dependant transcription. The study is a continuation of earlier work establishing the role of CITED1 in mammary gland development.<br/><br/>Results: CITED1 mRNA is associated with estrogen-receptor positivity and selectively expressed in the GOBO dataset of cell lines and tumours representing the luminal-molecular subtype. In patients treated with tamoxifen, higher CITED1 correlated with better outcome, suggesting a role in anti-estrogen response. The effect was particularly evident in the subset of estrogen-receptor positive, lymph-node negative (ER+/LN-) patients although noticeable divergence of the groups was apparent only after five years. Tissue microarray (TMA) analysis further validated the association of CITED1 protein, by immunohistochemistry, with favourable outcome in ER+, tamoxifen-treated patients. Although we also found a favourable response to anti-endocrine treatment in a larger TCGA dataset, the tamoxifen-specific effect was not replicated. Finally, MCF7 cells overexpressing CITED1 showed selective amplification of AREG but not TGFα suggesting that maintenance of specific ERα-CITED1 mediated transcription is important for the long-term response to anti-endocrine therapy. These findings together confirm the proposed mechanism of action of CITED1 and support its potential use as a prognostic biomarker.}},
  author       = {{Dahlgren, Malin and Lettiero, Barbara and Dalal, Hina and Mårtensson, Kira and Gaber, Alexander and Nodin, Björn and Gruvberger, Sofia and Saal, Lao H and Howlin, Jillian}},
  issn         = {{1756-0500}},
  keywords     = {{breast cancer; ER alpha; CITED1; tamoxifen; aromatase inhibitor; Anti-endocrine}},
  language     = {{eng}},
  month        = {{06}},
  number       = {{1}},
  publisher    = {{BioMed Central (BMC)}},
  series       = {{BMC Research Notes}},
  title        = {{CITED1 as a marker of favourable outcome in anti-endocrine treated, estrogen-receptor positive, lymph-node negative breast cancer.}},
  url          = {{http://dx.doi.org/10.1186/s13104-023-06376-1}},
  doi          = {{10.1186/s13104-023-06376-1}},
  volume       = {{16}},
  year         = {{2023}},
}